These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1469902)

  • 1. Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials.
    Freedman LS; Schatzkin A; Schiffman MH
    J Cell Biochem Suppl; 1992; 16G():27-32. PubMed ID: 1469902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermediate biomarkers of precancer and their application in chemoprevention.
    Kelloff GJ; Malone WF; Boone CW; Steele VE; Doody LA
    J Cell Biochem Suppl; 1992; 16G():15-21. PubMed ID: 1469895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate endpoint biomarkers for phase II cancer chemoprevention trials.
    Kelloff GJ; Boone CW; Crowell JA; Steele VE; Lubet R; Doody LA
    J Cell Biochem Suppl; 1994; 19():1-9. PubMed ID: 7823579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The study of markers of biological effect in cancer prevention research trials.
    Greenwald P; Witkin KM; Malone WF; Byar DP; Freedman LS; Stern HR
    Int J Cancer; 1992 Sep; 52(2):189-96. PubMed ID: 1521908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate markers as surrogate endpoints in cancer research.
    Schatzkin A
    Hematol Oncol Clin North Am; 2000 Aug; 14(4):887-905. PubMed ID: 10949779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of cancer.
    Tsao AS; Kim ES; Hong WK
    CA Cancer J Clin; 2004; 54(3):150-80. PubMed ID: 15195789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in chemoprevention of cancer.
    Hong WK; Sporn MB
    Science; 1997 Nov; 278(5340):1073-7. PubMed ID: 9353183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for Chemoprevention of Cancers of the Cervix, Endometrium and Ovary: Surrogate Endpoints and Design of Clinical Trials. Conference proceedings. Oxnard, California, February 1-5, 1995.
    J Cell Biochem Suppl; 1995; 23():1-250. PubMed ID: 8786651
    [No Abstract]   [Full Text] [Related]  

  • 14. Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
    Fabian CJ; Kimler BF
    Ann N Y Acad Sci; 2001 Dec; 952():44-59. PubMed ID: 11795443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention trials and surrogate end point biomarkers in the cervix.
    Mitchell MF; Hittelman WK; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Wharton JT; Hong WK
    Cancer; 1995 Nov; 76(10 Suppl):1956-77. PubMed ID: 8634987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention: will it work?
    Mettlin C
    Int J Cancer; 1997; Suppl 10():18-21. PubMed ID: 9209015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive clinical trials. An overview.
    Greenwald P
    Ann N Y Acad Sci; 1995 Sep; 768():129-40. PubMed ID: 8526342
    [No Abstract]   [Full Text] [Related]  

  • 18. Biomarkers in cancer chemoprevention. Workshop report.
    IARC Sci Publ; 2001; 154():1-12. PubMed ID: 11220649
    [No Abstract]   [Full Text] [Related]  

  • 19. Candidate biomarkers for application as intermediate end points of lung carcinogenesis.
    Mulshine JL; Linnoila RI; Treston AM; Scott FM; Quinn K; Avis I; Shaw GL; Jensen SM; Brown P; Birrer MJ
    J Cell Biochem Suppl; 1992; 16G():183-6. PubMed ID: 1469899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and endocrine biomarkers in non-involved breast: relevance to cancer chemoprevention.
    Telang NT; Bradlow HL; Osborne MP
    J Cell Biochem Suppl; 1992; 16G():161-9. PubMed ID: 1469896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.